Activation of β-catenin cooperates with loss of Pten to drive AR-independent castration-resistant prostate cancer.

Inhibition of the androgen receptor (AR) is the main strategy to treat advanced prostate cancers. AR-independent treatment-resistant prostate cancer is a major unresolved clinical problem. Prostate cancer patients with alterations in canonical WNT pathway genes, which lead to β-catenin activation, are refractory to AR-targeted therapies. Here using clinically relevant murine prostate cancer models, we investigated the significance of β-catenin activation in prostate cancer progression and treatment resistance. β-catenin activation, independent of the cell-of-origin, cooperated with Pten loss to drive AR-independent castration-resistant prostate cancer. Prostate tumours with β-catenin activation relied on the non-canonical WNT ligand WNT5a for sustained growth. WNT5a repressed AR expression and maintained the expression of c-Myc, an oncogenic effector of β-catenin activation, by mediating nuclear localization of NFƙBp65 and β-catenin. Overall, WNT/β-catenin and AR signalling are reciprocally inhibited. Therefore, inhibiting WNT/β-catenin signalling by limiting WNT secretion in concert with AR inhibition may be useful for treating prostate cancers with alterations in WNT pathway genes.

[1]  Yi Mi Wu,et al.  The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.

[2]  F. Hamdy,et al.  Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1 , 2018, EMBO molecular medicine.

[3]  David C. Smith,et al.  Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature , 2018, Molecular Cancer Research.

[4]  Wun-Jae Kim,et al.  WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages , 2018, British Journal of Cancer.

[5]  J. Lack,et al.  Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer. , 2017, European urology focus.

[6]  A. Clarke,et al.  PTEN loss and activation of K‐RAS and β‐catenin cooperate to accelerate prostate tumourigenesis , 2017, The Journal of pathology.

[7]  J. Isaacs,et al.  Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy. , 2017, Cancer cell.

[8]  Michael D. Nyquist,et al.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.

[9]  R. Kypta,et al.  WNT signalling in prostate cancer , 2017, Nature Reviews Urology.

[10]  Matti Nykter,et al.  Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.

[11]  Paul Workman,et al.  Drug discovery in advanced prostate cancer: translating biology into therapy , 2016, Nature Reviews Drug Discovery.

[12]  V. Arora,et al.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.

[13]  Joshua M. Stuart,et al.  A basal stem cell signature identifies aggressive prostate cancer phenotypes , 2015, Proceedings of the National Academy of Sciences.

[14]  C. Dang,et al.  MYC, Metabolism, and Cancer. , 2015, Cancer discovery.

[15]  Sridhar Ramaswamy,et al.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance , 2015, Science.

[16]  Chun-Ming Chen,et al.  Differential requirements for β‐catenin in murine prostate cancer originating from basal versus luminal cells , 2015, The Journal of pathology.

[17]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[18]  R. Luong,et al.  Androgen Signaling Is a Confounding Factor for β-catenin-mediated Prostate Tumorigenesis , 2015, Oncogene.

[19]  G. Yochum,et al.  Nuclear AXIN2 represses MYC gene expression. , 2014, Biochemical and biophysical research communications.

[20]  W. Sellers,et al.  Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974 , 2013, Proceedings of the National Academy of Sciences.

[21]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[22]  O. Sansom,et al.  Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. , 2013, The Journal of clinical investigation.

[23]  R. Cardiff,et al.  Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell of origin model for prostate cancer heterogeneity , 2013, Nature Cell Biology.

[24]  M. Taketo,et al.  β-Catenin Is Required for Prostate Development and Cooperates with Pten Loss to Drive Invasive Carcinoma , 2013, PLoS genetics.

[25]  R. Nusse,et al.  Wnt5a can both activate and repress Wnt/β-catenin signaling during mouse embryonic development. , 2012, Developmental biology.

[26]  Hans Clevers,et al.  Wnt/β-Catenin Signaling and Disease , 2012, Cell.

[27]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[28]  O. Sansom,et al.  HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer , 2011, Proceedings of the National Academy of Sciences.

[29]  I. Mills,et al.  The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis , 2011, The EMBO journal.

[30]  Sarat Chandarlapaty,et al.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.

[31]  S. Aaronson,et al.  Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. , 2010, Genes & development.

[32]  E. Bradley,et al.  WNT5A regulates chondrocyte differentiation through differential use of the CaN/NFAT and IKK/NF-kappaB pathways. , 2010, Molecular endocrinology.

[33]  Cora N. Sternberg,et al.  Castration-Resistant Prostate Cancer , 2010, Drugs.

[34]  F. Brembeck,et al.  Tumor stroma-derived Wnt5a induces differentiation of basal cell carcinoma of Ptch-mutant mice via CaMKII. , 2010, Cancer research.

[35]  O. Witte,et al.  Isolation, cultivation and characterization of adult murine prostate stem cells , 2010, Nature Protocols.

[36]  R. Goodman,et al.  A β-catenin/TCF-coordinated chromatin loop at MYC integrates 5′ and 3′ Wnt responsive enhancers , 2009, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Shen,et al.  A luminal epithelial stem cell that is a cell of origin for prostate cancer , 2009, Nature.

[38]  Julie A. Wilkins,et al.  Myc deletion rescues Apc deficiency in the small intestine , 2007, Nature.

[39]  H. Fehling,et al.  Faithful activation of an extra‐bright red fluorescent protein in “knock‐in” Cre‐reporter mice ideally suited for lineage tracing studies , 2007, European journal of immunology.

[40]  R. Nusse,et al.  Purified Wnt5a Protein Activates or Inhibits β-Catenin–TCF Signaling Depending on Receptor Context , 2006, PLoS biology.

[41]  D. Beach,et al.  Myc confers androgen-independent prostate cancer cell growth. , 2003, The Journal of clinical investigation.

[42]  W. Isaacs,et al.  Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor , 2002, Oncogene.

[43]  T. Sasaki,et al.  T cell-specific loss of Pten leads to defects in central and peripheral tolerance. , 2001, Immunity.

[44]  P. Roy-Burman,et al.  Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation , 2001, Mechanisms of Development.

[45]  M. Taketo,et al.  Intestinal polyposis in mice with a dominant stable mutation of the β‐catenin gene , 1999, The EMBO journal.

[46]  I. Fidler,et al.  Metastatic behavior of human tumor cell lines grown in the nude mouse. , 1984, Cancer research.

[47]  W. Isaacs,et al.  Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. , 2002, Oncogene.